Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10330431 | 0.87 | ALDH1A1 (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8049726 | 0.82 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8049724 | 0.82 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Amantadine SCHEMBL15009338 | 0.81 | TUBB4A (0.39) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14202563 | 0.80 | TUBB4A (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL14587592 | 0.78 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL20122158 | 0.78 | TUBB4A (0.54) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4093912 | 0.78 | PRNP (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL843065 | 0.78 | GPR3 (0.46) | GPR3ALDH1A1KDM4ELMNACASP1 | |
| SCHEMBL23430332 | 0.77 | TUBB4A (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12060358-B2 | Orally bioavailable, brain-penetrant compound with selectivity for the cannabinoid type 2 receptor with potential use towards visceral pain management and neurodegenerative disorders | UNIV MISSISSIPPI (US) | 2024-08-13 | — | — | US | disclosed |
| CN-115151541-B | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230303581-A1 | ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS | UNIV MISSISSIPPI (US) | 2023-09-28 | — | — | US | disclosed |
| EP-3330269-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2023-06-07 | — | — | EP | disclosed |
| EP-3330269-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYNTHESIS FOR BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| WO-1998006402-A1 | TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS | ELI LILLY AND COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998001436-A1 | HETEROAROMATIC PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
| US-5646144-A | FOR TREATING DISORDERS IN WHICH SUBSTANCE P PLAYS A PART IN DEVELOPMENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997013512-A1 | N-[2-SUBSTITUTED-3-(2-AMINOETHYL)-1H-INDOL-5-YL]-AMIDES: NEW 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1997-04-17 | — | — | WO | disclosed |
| EP-0768301-A1 | N-(2-substituted-3-(2-aminoethyl)-1H-indol-5-yl)-amides as new 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996040982-A1 | THERAPEUTIC INHIBITION OF PHOSPHOLIPASE A2 IN NEURODEGENERATIVE DISEASE | ATHENA NEUROSCIENCES, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5541195-A | SUBSTANCE P ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0532456-B1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA GEIGY AG (CH) | 1995-03-29 | — | — | EP | disclosed |
| US-5310743-A | Substance P antagonist | CIBA-GEIGY CORP. (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0532456-A1 | 1-Acylpiperidine derivatives and their use as substance P antagonists | CIBA-GEIGY AG (CH) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | LSS, PGLS, LDHB | TUBB4A 2388/4885TUBB 1116/4885TUBA3C 3398/4885 |
| US-12060358-B2 | Orally bioavailable, brain-penetrant compound with selectivity for the cannabinoid type 2 receptor with potential use towards visceral pain management and neurodegenerative disorders | CNR2, CNR1, OPRL1 | TUBB4A 3392/4885TUBB 2638/4885TUBA3C 3208/4885 |
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | TUBB4A 575/4885TUBB 434/4885TUBA3C 577/4885 |
| US-20230303581-A1 | ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS | CNR2, CNR1, OPRL1 | TUBB4A 3392/4885TUBB 2638/4885TUBA3C 3208/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | TUBB4A 2178/4885TUBB 989/4885TUBA3C 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.